Balderton leads $10m series-A for HealX

The funding round will enable HealX to more than double the size of its team with the recruitment of software engineers, data scientists, pharmacologists, drug development experts and commercial team members. It will also enable the company to invest in further product development.

Existing investor Amadeus Capital also took part in the round alongside angel investor Jonathan Milner, the co-founder and deputy chairperson of biotechnology company Abcam and a non-executive director at equity crowdfunding business Syndicate Room.

Previous funding
Amadeus invested £1.5m in HealX in October 2016, to fund the company's research activity and enable it to invest in the development of its technology platform.

Company
Founded in 2014, Cambridge-headquartered HealX combines artificial intelligence, pharmacology research and insights from patient groups to develop new approaches to treating rare diseases.

People
Balderton – Suranga Chandratillake (partner).
Amadeus Capital Partners – Hermann Hauser (partner, co-founder).
HealX – Tim Guilliams (co-founder, CEO); David Brown (co-founder, chief scientific officer).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• UK / Ireland
• Healthcare
• United Kingdom
• Balderton Capital
• Amadeus Capital
• Venture